|
Studies ask: what does “multimorbidity” mean and how much does it cost us?
April 4, 2023
Image Caption: Two new studies analyze the concept and costs of multimorbidity.
Image Credit: stevepb, Pixabay (CC0, https://creativecommons.org/publicdomain/zero/1.0/)
The prevalence of multimorbidity, the co-occurrence of two or more chronic conditions, varies depending on exactly how it is defined. And the healthcare costs associated with many disease combinations cost more together than the sum of each individual disease. Those are the conclusions of two new studies, publishing April 4th in the open access journal PLOS Medicine, that broadly analyze the concept and costs of multimorbidity.
Multimorbidity is increasing in prevalence due to improved survival from chronic diseases and population aging, and now poses major challenges to healthcare systems worldwide. The rise in healthcare spending in many developed countries and the prevalence of multimorbidity are interlinked but the relationship is not well understood.
In the first study, Clare MacRae of the University of Edinburgh, Scotland, and colleagues analyzed English primary care data on nearly 1.2 million people registered with 149 general medical practices. Using nine published lists of medical conditions, they showed that varying the individual conditions considered to contribute to multimorbidity leads to large differences when calculating multimorbidity prevalence. The prevalence of multimorbidity when only the two commonest conditions were considered was 4.6%, rising to 29.5% considering the 10 commonest, 35.2% considering the 20 commonest, and 40.5% when considering all 80 conditions. Across the whole population, 52 of the 80 possible conditions are/would be required to reach a multimorbidity prevalence of >99%. This varies according to age. However, in older populations, it was possible to consider fewer conditions (29 conditions for people over age 80), and in younger people, more conditions must be included (71 conditions for people under age 10) to reach accurate measurements of multimorbidity.
“There is a need for standardization when measuring multimorbidity prevalence so that results across studies are comparable and population subgroups are accurately represented,” the authors say.
In the second study, Angela Chang of the University of Southern Denmark, Copenhagen, and colleagues used data from private health insurance claims of more than 16 million unique enrollees ages 18 to 64 in the United States. Including 63 chronic conditions, the team found that 56.2% of the study population had at least two chronic conditions. When they looked at every possible two- or three-disease combinations, they discovered that 60.1% of disease combinations had super-additive spending, with the combination spending greater than the sum of the individual diseases. The diseases with both the highest cost per case and the highest contribution to multimorbidity spending were chronic kidney disease, liver cirrhosis, ischemic heart disease and inflammatory bowel disease.
“In the midst of surging health spending globally, and especially in the United States, pinpointing high-prevalence, high-spending conditions and super-additive disease combinations could help policymakers design interventions to improve treatment effectiveness and reduce spending,” the authors say.
Together, the papers underscore the need for innovative methods to study the prevalence and costs of multimorbidity. More work is needed to replicate and generalize estimates of multimorbidity prevalence and spending using standardized methods for these calculations to help inform policymakers and better direct resources for its management and prevention.
###
In your coverage, please use this URL to provide access to the freely available papers in PLOS Medicine:
http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004208
http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004205
Press-only previews: https://plos.io/3JQpZ92, https://plos.io/3ZdhXfZ
Contacts:
Contact 1: Clare MacRae, clare.macrae@ed.ac.uk, mobile: +44 07920425766
Contact 2: Angela Chang, achang@health.sdu.dk
Image Caption: Two new studies analyze the concept and costs of multimorbidity.
Image Credit: stevepb, Pixabay (CC0, https://creativecommons.org/publicdomain/zero/1.0/)
Image URL: https://plos.io/42H0QX9
Citation 1: MacRae C, McMinn M, Mercer SW, Henderson D, McAllister DA, Ho I, et al. (2023) The impact of varying the number and selection of conditions on estimated multimorbidity prevalence: A cross-sectional study using a large, primary care population dataset. PLoS Med 20(4): e1004208. https://doi.org/10.1371/journal.pmed.1004208
Citation 2: Chang AY, Bryazka D, Dieleman JL (2023) Estimating health spending associated with chronic multimorbidity in 2018: An observational study among adults in the United States. PLoS Med 20(4): e1004205. https://doi.org/10.1371/journal.pmed.1004205
Author Countries: United Kingdom, Denmark
Funding 1: This work was supported by the Chief Scientist Office (HIPS/18/30) to BG, SWM, DA, EJ, DM, NHS Education for Scotland Academic Fellowship for CM, and Medical Research Council MR/W000253/1 fellowship for CM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Funding 2: Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health (Award Number P30AG047845 to JLD and AYC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests 1: The authors have declared that no competing interests exist.
Competing Interests 2: The authors have declared that no competing interests exist.
About PLOS Medicine
PLOS Medicine is an open-access, peer-reviewed journal published by PLOS, featuring research articles of general interest on biomedical, environmental, social and political determinants of health. For more information visit http://journals.plos.org/plosmedicine/, or follow @PLOSMedicine on Twitter.
Media and Copyright Information
For information about PLOS Medicine relevant to journalists, bloggers and press officers, including details of our press release process and embargo policy, visit http://journals.plos.org/plosmedicine/s/press-and-media.
PLOS Journals publish under a Creative Commons Attribution License, which permits free reuse of all materials published with the article, so long as the work is cited.
About PLOS
PLOS is a nonprofit, Open Access publisher empowering researchers to accelerate progress in science and medicine by leading a transformation in research communication. We’ve been breaking boundaries since our founding in 2001. PLOS journals propelled the movement for OA alternatives to subscription journals. We established the first multi-disciplinary publication inclusive of all excellent research regardless of novelty or impact, and demonstrated the importance of open data availability. As Open Science advances, we continue to experiment to provide more opportunities, choice, and context for readers and researchers. For more information, visit https://www.plos.org/who-we-are.
Disclaimer
This press release refers to upcoming articles in PLOS Medicine. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
Source:
https://plos.org/
"Reproduced with permission - PLOS"
PLOS
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
